Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds and APIs
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Cured
December 09, 2017
Ash 2017 – An early beta-thalassaemia challenge from Glaxosmithkline
December 07, 2017
Ash therapy focus – the other amyloidosis gets its day in the sun
November 28, 2017
Immuno-oncology combos – what will be hot in 2018?
July 28, 2017
Upcoming events – FDA approvals due for Maviret and Besponsa
July 21, 2017
Snippet roundup: a lingering Lingo and two more US green lights
June 05, 2017
Asco – Mystery Chinese group gives Bluebird a run for its money
February 27, 2017
Merck’s Idenix write-off another bad sign in hep C
February 27, 2017
Merck’s Idenix write-off another bad sign in hep C
November 15, 2016
After the deluge, hep C players look for opportunity
September 07, 2016
How Gilead could go back to basics
July 27, 2016
Gilead lives and dies by hep C
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
April 20, 2022
Genetic Medicine: The Next Generation
March 18, 2022
PD(L)anner - March 2022
Editor's Picks
May 05, 2022
Bristol needs to get fresh
May 04, 2022
The next generation of diabetes technology
April 25, 2022
Nkarta: at least as good as Fate, at a tenth of the price
April 26, 2022
How Gal appointment could influence strategy at Novartis
May 01, 2020
US FDA approval tracker: April
